TELA TELA Bio, Inc.
USHealthcareAs of 2026-10-02
Why TELA matters now
TELA Bio, Inc. (TELA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.14 with -8.80% on the session and $51.0M in market capitalization; recent performance reads 1-month -6.86% and YTD -32.12%.
The latest financial table shown here is Q1 2026, with revenue of $19.1M, net income of $-12.3M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -84.2%.
The latest indexable market news headline is "Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.00; recent insider activity includes NOHRA GUY P filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-8.82
P/S
0.44
EV/EBITDA
-1.62
DCF Value
$1.39
FCF Yield
-84.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.3%
Operating Margin
-41.8%
Net Margin
-49.3%
ROE
-1344.5%
ROA
-57.0%
ROIC
-64.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $19.1M | $-12.3M | $-0.21 |
| Q4 2025 | $20.9M | $-9.0M | $-0.17 |
| FY 2025 | $80.3M | $-38.8M | $-0.83 |
| Q3 2025 | $20.7M | $-8.6M | $-0.19 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.25
Target (Median)
$3.00
Target Range
$1.25 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.33
Operating as a commercial-stage medical technology firm, TELA Bio, Inc. is dedicated to improving patient outcomes through advanced soft-tissue reconstruction solutions. Their approach emphasizes the preservation and restoration of the body's natural anatomy. The company offers a diverse portfolio of specialized products, including their flagship OviTex Reinforced Tissue Matrix, extensively utilized for hernia repair and abdominal wall reconstruction. Additionally, OviTex PRS Reinforced Tissue Matrix products cater to specific requirements within plastic and reconstructive surgery, addressing current gaps in treatment. They also provide a specialized OviTex variant designed for laparoscopic and robotic procedures. This sterile, reinforced tissue matrix is derived from ovine rumen and strengthened with polypropylene fiber, specifically engineered for use in minimally invasive hernia repairs. TELA Bio distributes its offerings primarily within the United States, utilizing a dedicated direct sales team. Established in 2012, TELA Bio, Inc. is headquartered in Malvern, Pennsylvania.